Skip to content
Sign in
Artwork for AudioScholar Hematology Weekly
Health & FitnessMedicine

AudioScholar Hematology Weekly

AudioScholar

Hematology — a weekly podcast briefing of the most significant peer-reviewed hematology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc.

Play
Open in
  • 22 episodes
  • weekly
  • Avg 12 min
  • English

Episodes 22

NewestOldestLongest
All20Unplayed20In progress0Played0
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • Wednesday · 10 min

    This Week in Hematology — Oct 7, 2026

    This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning bispecific antibodies moving into older and frailer patients, the fixed-duration versus continuous therapy debate in chronic lymphocytic leukemia, and genomic tools that sharp… This week's papers: Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients. — Blood 2026 A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma. — Blood 2026 Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study. — Blood Cancer Journal 2026 First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival. — Leukemia 2026 Diagnosis and Management of Chronic Lymphocytic Leukemia with TP53 Loss of Function in the Novel Agent Era. — Blood 2026 Functional Classification of Monoallelic TP53 Mutations Refines Prognostic Stratification in Myelodysplastic Neoplasms. — Blood 2026 Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study. — Blood 2026 Pembrolizumab-GVD in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter phase 2 trial. — Blood 2026 Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial. — Blood 2026 New FDA-Approved Treg Therapy to Reduce Chronic GVHD After Allogeneic HSCT. — Blood 2026 Listen at AudioScholar

  • September 30 · 13 min

    This Week in Hematology — Sep 30, 2026

    This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning lymphoid malignancy therapy and prognostication, thrombosis and antibody-mediated coagulopathy, and a new generation of prediction tools built on ordinary blood tests. Let's d… This week's papers: Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia. — Blood 2026 Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma. — British Journal of Haematology 2026 A randomized phase 2 placebo-controlled trial of clobetasol solution for oral chronic graft-versus-host disease therapy. — Blood Advances 2026 SENIOR-IPI: An easily applicable prognostic index for first-line large B-cell lymphomas patients >80 years treated with curative intent. — British Journal of Haematology 2026 Clinical and molecular characteristics of clonal monocytosis with and without cytopenia(s). — Leukemia 2026 Teclistamab for the treatment of autoantibody-mediated coagulation disorders. — Journal of Thrombosis and Haemostasis 2026 Endotheliopathy and VWF-ADAMTS13 axis dysfunction in VEXAS thrombogenicity. — Blood 2026 Development and validation of a model for stratifying haematological malignancy risk in primary care using basic blood tests. — British Journal of Haematology 2026 Intravenous Immunoglobulin (IVIG) use in HIT and efficacy of early IVIG compared to standard of care treatment. — Journal of Thrombosis and Haemostasis 2026 Machine learning models for suspected pulmonary embolism in emergency department patients: a multicentre diagnostic study. — Thrombosis and Haemostasis 2026 Listen at AudioScholar

  • September 23 · 12 min

    This Week in Hematology — Sep 23, 2026

    Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning acute leukaemia therapy and risk stratification, maintenance strategies and prognostic modelling in myeloma and CLL, and a pair of practical updates in thrombosis, plus a first-in-human mRNA immunotherapy. Let's dive in. We start with acute myeloid leukaemia, where a rare subtype may be about to change categor… This week's papers: Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia. — Blood 2026 Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients. — American Journal of Hematology 2026 How I Treat: MRD testing to personalize allogeneic HCT for adults with AML. — Blood 2026 Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups. — British Journal of Haematology 2026 Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial. — British Journal of Haematology 2026 Soluble BCMA Defines Spatial Phenotypes and Prognosis in Newly Diagnosed Multiple Myeloma. — Blood 2026 Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification-Insights from chromosome count and cytogenetic abnormalities. — British Journal of Haematology 2026 Perioperative Management of Patients on Factor XI or Factor XIa Inhibitors. — Journal of Thrombosis and Haemostasis 2026 Diagnosis and management of subsegmental pulmonary embolism. — Journal of Thrombosis and Haemostasis 2026 mRNA-encoding CD19-targeting T cell engager for refractory immune thrombocytopenia. — Cell 2026 Listen at AudioScholar

  • September 16 · 13 min

    This Week in Hematology — Sep 16, 2026

    Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning inherited red cell disorders and the anaemias, immune-based therapies moving earlier into plasma cell and acute leukaemia, and protein replacement strategies in bleeding and thrombotic microangiopathy. Let's dive in. We start with the red cell, and the biggest news comes from The Lancet, where Cappellini and c… This week's papers: Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. — The Lancet 2026 Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura: final analysis from a randomized phase 3 trial. — Blood 2026 Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial. — Nature Medicine 2026 Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline. — Annals of Internal Medicine 2026 FRONTIER5: Safety and patient experience of a direct switch from emicizumab to denecimig (Mim8) in patients with haemophilia A with or without inhibitors. — Journal of Thrombosis and Haemostasis 2026 Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment. — American Journal of Hematology 2026 Reduced-dose versus standard-dose total body irradiation before allogeneic haematopoietic stem cell transplantation in adults with acute lymphoblastic leukaemia. — British Journal of Haematology 2026 Sickle cell anaemia with and without crises: An observational study of pregnancy outcomes. — British Journal of Haematology 2026 Stroke incidence and phenotype in Saudi patients with sickle cell disease: A longitudinal cohort study. — British Journal of Haematology 2026 Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia. — Leukemia 2026 Listen at AudioScholar

  • September 9 · 12 min

    This Week in Hematology — Sep 9, 2026

    Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning risk stratification across myeloid and plasma cell disorders, salvage and supportive strategies in acute leukaemia and bone marrow failure, and a set of papers that ask us to rethink diagnostic thresholds — from haemoglobin cut-offs to how we biopsy for amyloid. Let's dive in. Let's start with acute myeloid le… This week's papers: Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium. — British Journal of Haematology 2026 How I Treat Pediatric Hematology-Oncology Patients from Families Identifying as Jehovah's Witnesses. — Blood 2026 Association Between Blood Hemoglobin Concentration and Mortality by Age and Sex : A Prospective Cohort Study. — Annals of Internal Medicine 2026 Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma. — Leukemia 2026 Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents. — British Journal of Haematology 2026 Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy. — Leukemia 2026 Diagnostic Accuracy of Fat Pad Sampling and Bone Marrow Biopsy for AL Amyloidosis: A Systematic Review and Meta-Analysis. — Blood Advances 2026 Age- and sex-adjusted genomic differences between Korean and Beat AML cohorts. — Blood Advances 2026 Age as a core disease modifier: Distinct clinical, molecular and prognostic landscapes of essential thrombocythaemia in adolescents and young adults. — British Journal of Haematology 2026 ADAMTS13 fusion constructs with dual activity against VWF: a novel strategy for iTTP. — Journal of Thrombosis and Haemostasis 2026 Listen at AudioScholar

  • September 2 · 12 min

    This Week in Hematology — Sep 2, 2026

    Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning three broad territories: curative and disease-modifying therapy in the haemoglobinopathies, immunotherapy-era risk stratification in acute lymphoblastic leukaemia, and how we choose salvage and transplant strategies in myeloid disease and chronic lymphocytic leukaemia. Let's dive in. We'll start with sickle ce… This week's papers: HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities — American Journal of Hematology 2026 Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort — American Journal of Hematology 2026 Early response and genetics define relapse risk after frontline blinatumomab in childhood B-ALL: a cohort study — Blood Advances 2026 Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome — Leukemia 2026 Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study — American Journal of Hematology 2026 Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid leukemia: a COMMAND registry study — Leukemia 2026 Relationship Between Salvage Strategy and Outcomes in Patients With CBF or NPM1-mutated AML and First Molecular Relapse — Blood Advances 2026 Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma — British Journal of Haematology 2026 Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV, open-label, single-centre trial — British Journal of Haematology 2026 Efficacy and safety of thalidomide (1 vs 2 mg/kg/d) in transfusion-dependent thalassemia: A Non-Inferiority Trial — Blood Advances 2026 Listen at AudioScholar

  • August 26 · 11 min

    This Week in Hematology — Aug 26, 2026

    Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning plasma cell disorders and risk stratification, myeloid disease genetics and transplantation, lymphoma and rare leukemia management, and one hard look at anticoagulation monitoring in pregnancy. Let's dive in. We start with plasma cell disorders, where the headline is long-term survival. In Leukemia, Facon and… This week's papers: Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis. — Leukemia 2026 The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline. — British Journal of Haematology 2026 International Consensus Criteria for the Diagnosis, Treatment Initiation, and Response Assessment for T-LGL Leukemia. — Blood 2026 Real-world effectiveness and safety of Zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma. — Blood Advances 2026 Enhanced prognosis of acute myeloid leukaemia patients with dmCEBPAbZIP-inf mutations: Insights from a multicentre Chinese cohort study. — British Journal of Haematology 2026 Myeloma Elderly Prognostic Score (MEPS): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra-High-Risk Cytogenetics. — American Journal of Hematology 2026 Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival. — American Journal of Hematology 2026 Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents. — American Journal of Hematology 2026 Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy. — American Journal of Hematology 2026 The role of anti-Factor-Xa monitoring in the dosing and administration of low molecular weight heparins in pregnancy: a systematic review and meta-analysis. — Journal of Thrombosis and Haemostasis 2026 Listen at AudioScholar

  • August 19 · 11 min

    This Week in Hematology — Aug 19, 2026

    Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning bone marrow failure and myeloproliferative disease, blood-based disease monitoring in myeloma and lymphoma, and real-world outcomes with the targeted and cellular therapies we now use every day. Let's dive in. Let's start with two randomised trials in Blood that both challenge a treatment ceiling. The EMAA tri… This week's papers: Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial. — Blood 2026 Sapablursen for Erythrocytosis Control in Patients with Polycythemia Vera. — Blood 2026 Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results. — Blood 2026 Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial. — British Journal of Haematology 2026 Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study. — British Journal of Haematology 2026 Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma. — Haematologica 2026 Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FLT3-mutated acute myeloid leukaemia patients: A multicentre real-world study. — British Journal of Haematology 2026 Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy. — British Journal of Haematology 2026 Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes. — Haematologica 2026 Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study. — British Journal of Haematology 2026 Listen at AudioScholar

  • August 12 · 13 min

    This Week in Hematology — Aug 12, 2026

    Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning thrombosis risk stratification and antibody-mediated clotting, long-term outcomes in lymphoma and myeloma immunotherapy, and the diagnosis and management of under-recognised benign hematology conditions. Let's dive in. We start with a paper that challenges one of the most entrenched rules in thrombosis practic… This week's papers: Risk of recurrence in patients with provoked venous thromboembolism: a prospective cohort study. — Blood 2026 Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study. — Blood 2026 How I treat bleeding in women and girls with hemophilia/hemophilia carriers. — Blood 2026 Long-term follow-up of PET/CT-adapted therapy after three cycles of ABVD for all stages of classic Hodgkin lymphoma: Results of the GATLA LH-05 trial. — British Journal of Haematology 2026 Decade-long persistence of CD19 CAR T cells in B cell lymphomas. — Nature Medicine 2026 How I treat autoimmune neutropenia in adults. — Blood 2026 Monoclonal Gammopathy of Thrombotic Significance. — American Journal of Hematology 2026 A quantitative definition of the clinical manifestations of GATA2 deficiency in adults. — Blood 2026 Association between Pulmonary Vascular Obstruction Phenotype and Pulmonary Embolism Recurrence: Results from the PADIS-PE Study. — Thrombosis and Haemostasis 2026 Prevalence and thrombotic risk of PF4-dependent platelet-activating antibodies. — Journal of Thrombosis and Haemostasis 2026 Listen at AudioScholar

  • August 6 · 10 min

    This Week in Hematology — Aug 5, 2026

    Welcome to This Week in Hematology. This week we're covering nine notable papers spanning myeloma therapeutics and supportive care, the myeloproliferative neoplasms, and a cluster of bleeding-and-clotting papers with immediate bedside relevance, plus new work on how we phenotype sickle cell disease. Let's dive in. We'll start with multiple myeloma, where two papers approach the same disease from… This week's papers: Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200 — Blood Advances 2026 Systemic Bevacizumab for Severe Bleeding From Acquired Gastrointestinal Vascular Malformations — American Journal of Hematology 2026 High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients — British Journal of Haematology 2026 Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era — British Journal of Haematology 2026 Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia — Journal of Thrombosis and Haemostasis 2026 Identification of Clinical Sub-Phenotypes of Sickle Cell Disease Using Latent Class Analysis — American Journal of Hematology 2026 Classic Hodgkin Lymphoma: A Review — JAMA 2026 In a nutshell review of hereditary antithrombin deficiency in pregnancy — British Journal of Haematology 2026 Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis — Leukemia 2026 Listen at AudioScholar

  • July 31 · 14 min

    This Week in Hematology — Jul 31, 2026

    Welcome to This Week in Hematology. This week we're covering 9 notable papers spanning advances in myeloid neoplasms and clonal hematopoiesis, optimization of frontline lymphoma and leukemia therapies, and new insights into managing cellular therapy toxicities. Let's dive in. We begin with a prospective study published in Blood that tackles the challenging boundary between clonal cytopenia of und… This week's papers: Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826) — Blood Advances 2026 Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms — Blood 2026 Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML — Blood Advances 2026 Robust CD4CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma — Science Translational Medicine 2026 Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome — Blood Advances 2026 Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia — Blood Advances 2026 Real-world investigation of germline predisposition to myelodysplastic syndromes — Blood Advances 2026 Characteristics of Donor and Recipient Clonal Hematopoiesis in Nonmyeloablative Transplant for Sickle Cell Disease — Blood 2026 Long-term efficacy and safety of romiplostim plus immunosuppressive therapy as first-line treatment in patients with aplastic anaemia: 2-year interim analysis of observational study of two clinical trials — British Journal of Haematology 2026 Listen at AudioScholar

  • July 22 · 8 min

    This Week in Hematology — Jul 22, 2026

    Welcome to This Week in Hematology. This week we're covering 8 notable papers spanning severe aplastic anemia management, acute myeloid leukemia prognostication and measurable residual disease, and plasma cell dyscrasias. Let's dive in. In the realm of bone marrow failure, optimizing initial immunosuppression remains a critical clinical goal. The phase-3 randomized superiority EBMT-SAAWP RACE stu… This week's papers: Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study. — American journal of hematology 2026 Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry. — Leukemia 2026 Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma. — Blood cancer journal 2026 Upfront Autologous Stem Cell Transplantation in First Complete Remission for Advanced-Stage Extra-Nodal NK/T-Cell Lymphoma: A Multicenter Retrospective Study. — American journal of hematology 2026 Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy. — American journal of hematology 2026 Efficacy and Safety of BCMA-Targeted Therapies in Relapsed or Refractory AL Amyloidosis: A Descriptive Pooled Analysis. — Blood advances 2026 Management and long-term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia-related neuropathy: A single-centre experience. — British journal of haematology 2026 A Prospective Study of Familial Predisposition in Plasma Cell Dyscrasias. — Blood advances 2026 Listen at AudioScholar

  • July 15 · 16 min

    This Week in Hematology — Jul 15, 2026

    Welcome to This Week in Hematology. This week we are covering ten notable papers spanning clinical advances in malignant hematology, evolving strategies in non-malignant disorders like hemophilia and sickle cell disease, and critical safety insights in stem cell transplantation. Let us dive in. We begin in the realm of malignant hematology, where optimizing therapy for high-risk and medically unf… This week's papers: Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms — Leukemia 2026 Recurrent VTE in patients with thrombophilia after stopping anticoagulation - A systematic review and meta-analysis — Blood Advances 2026 Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis — Blood Cancer Journal 2026 Unmet needs despite standard-of-care prophylaxis in Hemophilia A: improved outcomes after switching to Efanesoctocog Alfa — Blood Advances 2026 FVIII exposure, bleeding outcomes, and inhibitor development in 80 PUPs and MTPs with severe hemophilia A on emicizumab prophylaxis: real world data from the PedNet Registry — Journal of Thrombosis and Haemostasis 2026 Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study — British Journal of Haematology 2026 Infection Burden in Mismatched Unrelated Donor Hematopoietic Cell Transplantation: Results from the ACCESS Trial — Blood Advances 2026 Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia — Leukemia 2026 Seroprotection after Measles Vaccination in Children with Sickle Cell Anemia Receiving Hydroxyurea — Blood Advances 2026 Blood Rheology After Allogeneic Hematopoietic Stem Cell Transplantation or Gene Therapy in Sickle Cell Disease — Blood Advances 2026 Listen at AudioScholar

  • July 8 · 17 min

    This Week in Hematology — Jul 8, 2026

    Welcome to This Week in Hematology. This week we are covering eight notable papers spanning advances in cellular immunotherapies, optimization of plasma cell disorder regimens, and novel risk stratification and supportive care strategies in hematologic conditions. Let's dive in. We begin this week with major developments in immunotherapy and chimeric antigen receptor, or CAR, T-cell therapies. In… This week's papers: Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm. — Blood 2026 Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma. — Blood 2026 Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma. — British Journal of Haematology 2026 How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists. — Blood 2026 High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone >= 1. — American Journal of Hematology 2026 Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies. — Blood Cancer Journal 2026 POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management. — American Journal of Hematology 2026 Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting. — British Journal of Haematology 2026 Listen at AudioScholar

  • July 1 · 15 min

    This Week in Hematology — Jul 1, 2026

    Welcome to This Week in Hematology. This week we are covering ten notable papers spanning three major areas: myeloid malignancies including myelofibrosis, myelodysplastic syndromes, and acute myeloid leukemia; lymphoid neoplasms featuring chronic lymphocytic leukemia, acute lymphoblastic leukemia, and classic Hodgkin lymphoma; and key updates in benign hematology, thrombosis, and bleeding disorder… This week's papers: TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis. — Blood 2026 Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database. — Blood Cancer Journal 2026 Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia. — Blood Cancer Journal 2026 Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs. — Blood Advances 2026 Diagnosis and management of neutropenia in adults: Expert guidance. — British Journal of Haematology 2026 Venous Thromboembolism in Women on Estrogen Therapy: Presentation, Management, and Outcomes in the RIETE registry. — Blood Advances 2026 One-stage Assay Factor VIII Activity Reflects AAV-Derived Factor VIII-Enhanced Thrombin Activation and Predicts Phenotype. — Blood 2026 Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial. — American Journal of Hematology 2026 Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma. — Blood Advances 2026 Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers. — Blood Cancer Journal 2026 Listen at AudioScholar

  • June 25 · 14 min

    This Week in Hematology — Jun 24, 2026

    Welcome to This Week in Hematology. This week we are covering nine notable papers spanning advanced cellular therapies and precision monitoring in lymphomas, optimized treatment protocols in chronic lymphocytic leukemia and hemophilia, and novel systemic interventions in thrombosis and immunology. Let us dive in. We begin with a milestone in cellular immunotherapy. CD19-directed chimeric antigen… This week's papers: Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma. — Blood cancer journal 2026 Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial. — Lancet (London, England) 2026 Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study. — Lancet (London, England) 2026 Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study. — Blood advances 2026 Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma. — Blood advances 2026 Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium Analysis. — Blood advances 2026 Prevention and Treatment of Peanut Allergy. — The New England journal of medicine 2026 Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. — The New England journal of medicine 2026 SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL. — Blood advances 2026 Listen at AudioScholar

  • June 18 · 10 min

    This Week in Hematology — Jun 17, 2026

    Welcome to This Week in Hematology. This week we're covering 8 notable papers spanning advances in diagnosing and treating lymphoma, new strategies in thrombosis and hemostasis, and innovations in cellular therapy and infectious disease management. Let's dive in. We begin this week in malignant hematology, with new data on first-line therapy for mantle cell lymphoma, a powerful diagnostic tool fo… This week's papers: Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma. — American journal of hematology 2026 Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma. — Blood advances 2026 The IL-10/IL-6 Ratio and the Risk Score: Two Cytokines-Based Predictors for Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Adults (M-HLHa). — American journal of hematology 2026 Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation. — Science translational medicine 2026 Long-term outcomes with emicizumab prophylaxis for haemophilia A in China: A multicentre, large-cohort retrospective study. — British journal of haematology 2026 Cefazolin for Methicillin-SusceptibleBacteremia. — The New England journal of medicine 2026 Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation. — Science translational medicine 2026 Plasma proteomic signatures of cellular aging predict human disease. — Nature medicine 2026 Listen at AudioScholar

  • June 11 · 10 min

    This Week in Hematology — Jun 10, 2026

    Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning advances in allogeneic transplant strategies, the growing role of molecular biomarkers in managing hematologic malignancies, and new therapeutic approaches for benign and genetic blood disorders. Let's dive in. First up, we have two papers looking at optimizing allogeneic stem cell transplantation, one focusin… This week's papers: TRACTION for Greater Surgical Use of Tranexamic Acid. — The New England journal of medicine 2026 CSF ctDNA Molecular Clearance as a Prognostic Biomarker for Orelabrutinib-Treated Primary Central Nervous System Lymphoma: Insights From Comparison With PET-CT. — American journal of hematology 2026 Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports. — BMJ (Clinical research ed.) 2026 Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial. — Blood advances 2026 Sirolimus for Refractory/relapsed Warm Autoimmune Hemolytic Anemia and Evans' syndrome: A Prospective Study. — Blood advances 2026 Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents. — American journal of hematology 2026 Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia. — Leukemia 2026 Hypertension. — Annals of internal medicine 2026 Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study. — Blood 2026 Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion-Dependent β-Thalassemia. — American journal of hematology 2026 Listen at AudioScholar

  • June 5 · 12 min

    This Week in Hematology — Jun 4, 2026

    Welcome to This Week in Hematology. This week we're covering 8 notable papers spanning new therapeutic strategies in lymphoma and leukemia, fundamental new insights into hemostasis, and a key trial in pediatric hyperinflammation. Let's dive in. First, we look at long-term outcomes and novel targets in lymphoid malignancies. A report in *Blood* presents the five-year survival outcomes from the TR… This week's papers: HLHRUXO: A prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis. — Blood advances 2026 Novel therapies for von Willebrand Disease. — Blood advances 2026 AKT inhibitor capivasertib reverses EVI1-driven resistance to venetoclax in acute myeloid leukaemia. — British journal of haematology 2026 GLUL pitches in thrombocytopoiesis by restricting ammonia accumulation during megakaryocyte maturation. — Blood 2026 ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia. — Blood 2026 Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL. — Blood 2026 PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma. — Blood 2026 Listen at AudioScholar

  • May 28 · 12 min

    This Week in Hematology — May 28, 2026

    Welcome to This Week in Hematology. This week we're covering seven notable papers spanning measurable residual disease in AML, the fundamental biology of stem cell aging, and clinical challenges in treating hematologic disorders. Let's dive in. Our first theme is the evolving landscape of measurable residual disease, or MRD, in acute myeloid leukemia. We know that detecting MRD before an allogene… This week's papers: Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis. — Haematologica 2026 Next generation sequencing-based measurable residual disease detection predicts outcomes in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. — Haematologica 2026 Human haematopoietic stem cells remember inflammatory stress. — Nature 2026 Mechanism of age-related accumulation of mtDNA mutations in human blood. — Nature 2026 Autoimmune cytopenias following alemtuzumab-induced renal transplant: clinical features and treatment outcomes. — Haematologica 2026 Identification of GSE1 as a PAX5 fusion partner and characterization of PAX5 fusion signature in B-cell acute lymphoblastic leukaemia. — British journal of haematology 2026 Adverse Effects and Treatment Discontinuation of Blood Pressure-Lowering Drugs and Combinations: A Network Meta-Analysis. — JAMA 2026 Listen at AudioScholar

Showing 1–20 of 22 episodes